Abstract:BACKGROUND:Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin.METHODS:The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining.RESULTS:Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt, which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice (22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment (16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation and tumor angiogenesis in vivo.CONCLUSION:The combination of rapamycin with bortezomib could be a novel and promising therapeutic approach to the treatment of HCC.

Synergistic Antitumor Activity of Rapamycin and EF24 Via Increasing ROS for the Treatment of Gastric Cancer.

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

Synergistic Effects of Rapamycin and Fluorouracil to Treat a Gastric Tumor in a PTEN Conditional Deletion Mouse Model

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors

CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer Through Abrogating Mtor Inhibition-Induced Phosphorylation of Eif4e and Activating Mitochondrial Apoptotic Pathway.

The Mtor Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells

Novel Synergistic Antitumor Effects of Rapamycin with Bortezomib on Hepatocellular Carcinoma Cells and Orthotopic Tumor Model

Combined Treatment Of Mitoxantrone Sensitizes Breast Cancer Cells To Rapalogs Through Blocking Eef-2k-Mediated Activation Of Akt And Autophagy

ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer.

Ethaselen Synergizes with Oxaliplatin in Tumor Growth Inhibition by Inducing ROS Production and Inhibiting TrxR1 Activity in Gastric Cancer

Rapamycin And Trametinib: A Rational Combination For Treatment Of Nsclc

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer

Combination of Rapamycin and Garlic-Derived S-allylmercaptocysteine Induces Colon Cancer Cell Apoptosis and Suppresses Tumor Growth in Xenograft Nude Mice Through Autophagy/p62/nrf2 Pathway.

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.

Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.

OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.

OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma

Synergistic induction of autophagy in gastric cancer by targeting CDK4/6 and MEK through AMPK/mTOR pathway

[Synergistic Effect of Rapamycin (RPM) and PD98059 on Cell Cycle and Mtor Signal Transduction in Human Colorectal Cancer Cells].